Genomics & Omics Analysis - software & AI news

Daily news on software, AI, and companies shaping genomics & omics analysis.

Showing 47 results
A flat design of a liquid biopsy tube with a drop of liquid, symbolizing molecular diagnostics.

May 10, 2026

Qiagen N.V. stock (NL0012169213): Life science tools firm eyes growth in molecular diagnostics and p

Qiagen N.V. is strategically enhancing its portfolio in molecular diagnostics, focusing on growth opportunities in oncology, infectious diseases, and precision medicine.As a prominent entity in the life sciences tools and diagnostics market, Qiagen N.V. specializes in sample preparation technologies, assay kits, and bioinformatics software. The company's commitment to advancing next-generation sequencing and liquid biopsy techniques positions it favorably within the evolving landscape of genomic
Flat design illustration of a test tube and DNA strand representing cancer diagnostics

May 9, 2026

Should Caris’s Q1 Revenue Surge and New AI Cancer Tests Require Action From Caris Life Sciences (CAI) Investors?

Caris Life Sciences has reported a significant revenue increase in Q1 2026, driven by new AI-based cancer diagnostic tests, prompting a reevaluation of its investment potential.In early May 2026, Caris Life Sciences announced a first-quarter revenue of $216.17 million, a substantial rise from $120.92 million in the same period last year. The company also reported a narrowed net loss of $0.51 million, down from $102.58 million. This financial growth coincides with the introduction of the AI-drive
A flat illustration of a cell with a highlighted biomarker in a minimalist design.

May 7, 2026

Israeli-founded AI biotech Immunai expands AstraZeneca cancer collaboration

Immunai, an AI biotech founded in Israel, has announced an expanded collaboration with AstraZeneca focused on oncology, potentially yielding up to $37.5 million over the next two years.This new agreement extends their multi-year partnership, allowing AstraZeneca to utilize Immunai's AMICA-OS AI operating system. This platform integrates clinical immunology data at a single-cell level with advanced AI models, aimed at enhancing oncology drug development through biomarker discovery, patient strati
A DNA sequencing sample on a lab bench in a dimly lit laboratory.

May 7, 2026

DNAnexus Wins MedTech Breakthrough’s PharmaTech Innovation Award

DNAnexus has been recognized with the PharmaTech Innovation Award at the 10th annual MedTech Breakthrough Awards, highlighting its significant contributions to precision medicine through its AI-driven orchestration platform.This award acknowledges DNAnexus as a pivotal player in the biopharma landscape, particularly for its ability to convert complex multimodal data into actionable scientific insights. The MedTech Breakthrough Awards program, known for its rigorous evaluation process, assessed o
A minimalist illustration of a DNA strand representing genomic diagnostics.

May 6, 2026

Moonlight AI secures €2.8 million to advance genomic diagnostics

Moonlight AI, a Swiss startup focusing on AI-driven cancer diagnostics, has successfully secured €2.8 million in Seed funding to enhance its innovative technology.This funding round was co-led by Lotus One Investment, VP Venture Partners, and MEDIN Fund, with additional support from N&V Capital and existing investor QAI Ventures. Founded in 2022, Moonlight AI aims to democratize genomic data access, facilitating precise cancer diagnostics without the need for expensive Next-Generation Sequencing
A blood sample and microscope in a dimly lit lab setting

May 6, 2026

Swiss startup Moonlight AI raises €2.8 million to turn routine blood and cytology imaging into genomic insights

Swiss startup Moonlight AI has secured €2.8 million in Seed funding to enhance diagnostic capabilities through innovative image analysis technology.Moonlight AI, established in 2022, is focused on developing AI-driven solutions for clinical diagnostics, specifically aiming to transform routine blood and cytology imaging into actionable genomic insights. The recent funding round was co-led by notable investors including Lotus One Investment and VP Venture Partners, with the goal of democratizing
A minimalist illustration of a breast and a pathology slide on a solid background.

May 5, 2026

Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis

Caris Life Sciences has introduced Caris MI Clarity, a groundbreaking AI-powered test aimed at predicting both early and late distant recurrence risks in postmenopausal patients diagnosed with HR-positive/HER2-negative, node-negative early-stage breast cancer. This innovative test promises to deliver results to physicians within three business days, significantly faster than traditional methods.The Caris MI Clarity test utilizes a proprietary dataset comprising thousands of breast cancer samples
A minimalist illustration of a DNA strand on a solid background.

May 4, 2026

Genient Enters Growth Phase with New CEO, Strategic AIT Biotech Partnership

Genient is poised for significant growth as it transitions into a specialized player in clinical genomics and molecular diagnostics, driven by new leadership and strategic partnerships.Founded in 2017 and based in Noida, Genient has evolved from a technology services provider to a focused entity in clinical genomics, aligning its offerings with India's increasing demand for data-driven diagnostics. The company targets critical areas such as infectious diseases, antimicrobial resistance, oncology
A genomic sample in a petri dish on a lab bench

May 4, 2026

Genient Charts New Path with Landmark Partnership in Genomic Diagnostics

Genient is embarking on a transformative journey in genomic diagnostics through a significant partnership with AIT Biotech, aimed at addressing the growing demand for advanced healthcare solutions in India.Based in Noida, Genient is enhancing its strategic direction under the leadership of Mr. Anil Kumar and newly appointed CEO Mr. Brijesh Singh. This partnership with AIT Biotech, located in Singapore, marks a pivotal shift for the company as it moves from technology services to a concentrated f
A minimalist representation of a liquid biopsy tube and a biomarker icon in flat design.

May 3, 2026

Guardant Health Partners with Nuvalent to Advance Precision Oncology

Guardant Health is entering a strategic partnership with Nuvalent to enhance precision oncology through improved biomarker-driven drug development.This collaboration aims to optimize patient selection and streamline clinical trials by integrating Guardant’s Infinity platform with Nuvalent’s oncology pipeline. By utilizing both tissue and liquid biopsy solutions, the partnership intends to refine the identification of patient populations suitable for targeted cancer therapies.As part of this init
A minimalist representation of a CAR-T cell and lymphocyte in a dark palette.

May 2, 2026

Is Growing Focus On CAR-T Data And CARVYKTI Orders Reframing Legend Biotech’s (LEGN) Investment Story?

Legend Biotech is increasingly in the spotlight as analysts focus on its CAR-T pipeline and the strength of CARVYKTI orders, particularly with upcoming clinical data readouts on the horizon.The company recently participated in the Cell & Gene Meeting on the Mediterranean and is set to discuss its first-quarter 2026 results in an upcoming investor call. Analysts are optimistic about Legend's CAR-T developments, linking the strong order book for CARVYKTI to anticipated clinical updates. This creat
A blood droplet and heart silhouette representing cardiovascular diagnostics.

May 2, 2026

Cardio Diagnostics Advances Early Detection of Heart Disease Using AI and Biomarkers

Cardio Diagnostics Holdings is leveraging artificial intelligence and biomarker analysis to enhance the early detection of cardiovascular disease, a leading cause of death globally.The company’s innovative platform utilizes a blood sample to provide personalized cardiovascular insights, merging genetic and epigenetic biomarkers with AI technology. This approach is particularly timely given the pressing need for effective solutions to combat cardiovascular disease, which significantly impacts ind